![Esther Rajavelu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Esther Rajavelu
Amministratore Delegato presso
SPERO THERAPEUTICS, INC.
Patrimonio netto: 1 M $ in data 31/07/2026
Profilo
Esther Rajavelu is currently President, CEO, CFO, Treasurer & Director at Spero Therapeutics, Inc. since 2025.
Former positions include Chief Financial Officer & Treasurer at Fulcrum Therapeutics, Inc. from 2022 to 2023; Senior Equities Research Analyst at UBS Securities LLC from 2020 to 2022; Executive Director & Senior Analyst at Oppenheimer & Co., Inc. (Broker) from 2018 to 2020; Research Analyst at Deutsche Bank Securities, Inc. from 2014 to 2018; Vice President-Life Sciences at Ernst & Young Capital Advisors LLC from 2011 to 2014; Vice President at Merrill Lynch, Pierce, Fenner & Smith, Inc.; Analyst at J.P.
Morgan & Co., Inc. (Old); Associate at Towers Perrin Capital Markets, Inc. Education includes undergraduate degree from Wesleyan University and MBA from The Wharton School of the University of Pennsylvania.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 04/05/2026 | 986.851 ( 1,7% ) | 1 M $ | 31/07/2026 |
Posizioni attive di Esther Rajavelu
| Società | Posizione | Inizio |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Amministratore Delegato | 10/01/2025 |
Precedenti posizioni note di Esther Rajavelu
| Società | Posizione | Fine |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Direttore Finanziario/CFO | 21/04/2023 |
UBS Securities LLC
 UBS Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01/01/2022 |
Oppenheimer & Co., Inc. (Broker)
 Oppenheimer & Co., Inc. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01/01/2020 |
Deutsche Bank Securities, Inc.
 Deutsche Bank Securities, Inc. Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01/06/2018 |
Ernst & Young Capital Advisors LLC
 Ernst & Young Capital Advisors LLC Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | 01/01/2014 |
Formazione di Esther Rajavelu
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
92
Relazioni di 1° grado
11
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 11 |
|---|---|
Deutsche Bank Securities, Inc.
Deutsche Bank Securities, Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
UBS Securities LLC
UBS Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Towers Perrin Capital Markets, Inc. | |
J.P. Morgan & Co., Inc. (Old)
 J.P. Morgan & Co., Inc. (Old) Regional BanksFinance Provides commercial banking and investment advisory services | Finance |
Oppenheimer & Co., Inc. (Broker)
Oppenheimer & Co., Inc. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Wesleyan University
 Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merrill Lynch, Pierce, Fenner & Smith, Inc.
 Merrill Lynch, Pierce, Fenner & Smith, Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Ernst & Young Capital Advisors LLC
Ernst & Young Capital Advisors LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Spero Therapeutics, Inc.
 Spero Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of bacterial infections | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
